继2024年交出"上市20年来首亏"成绩单后，双鹭药业（002038）去年业绩预计延续亏损并呈现亏损扩大的态势。 据2025年三季报，双鹭药业前三季度归母净利润1.41亿元，同比增幅达943.10%，主要系报告期内公司持有的首药控股、星昊医药等交易性金融资产公允 价值变动收益同比增加所致。具体而言，2024年1月~9月公司确认公允价值变动损失1.22亿元，而2025年同期则实现公允价值变动收益 1.28亿元，同比增 长达204.93%。但这种收益本质上是非经常性的，无法形成稳定盈利能力。 | | | | | | 早化: 月元 | | --- | --- | --- | --- | --- | --- | | 项目 | 本报告期 | | | | 上年同期 | | 归属于上市公司股 东的净利润 | | -29,000 | 2 | -20,000 | -7. 406. 57 | | | 比上年同期下降 | 291. 54% | N | 170. 03% | | | 扣除非经常性损益 后的净利润 | | -7.000 | ~ | -4. 000 | 8. 233. 70 | | | 比上年同期下降 | 185. 02 ...

日前，双鹭药业（002038.SZ）发布2025年业绩预告，预计2025年归母净利润为-2.90亿至-2.00亿元，同 比下降291.54%至170.03%；预计扣非净利润为-7000万至-4000万元，同比下降185.02%至148.58%。 业绩亏损的原因，双鹭药业列出两点： 一是受行业政策调整与市场竞争影响，公司部分产品单价下降，导致相关产品销售毛利下降约10%。二 是非经常性损益合计减少净利润约2亿元，其中理财投资损失与交易性金融资产公允价值变动收益是主 要影响因素。 来源：经理人网 编辑：曹諵 校对：知晏 本文仅供信息分享，不构成对任何人的任何投资建议， 如有侵权，请联系删除。 双鹭药业1994年成立，2004年9月在深交所上市，其主营业务广泛覆盖肿瘤、心脑血管、抗感染免疫、 代谢病、创伤修复、肝病、肾病及罕见病等多个治疗领域，一度被视为"药中茅台"。 不过近年来，受到市场竞争加剧、产品集采降价等因素影响，双鹭药业的多款产品收入下滑，主营业务 受挫，其就开始热衷频"炒股"。 财报数据显示，2024年，双鹭药业实现营业收入约6.6亿元，同比下降35.15%；归属于母公司股东的净 利润为-7407万元， ...

双鹭药业表示，报告期内，受行业政策调整、市场竞争等因素影响，公司部分产品单价较上年有所下 降，导致本年度公司相关产品的销售毛利下降约10%。此外，报告期内，公司非经常性损益合计减少净 利润约2亿元，其中确认的理财投资损失与交易性金融资产等产生的公允价值变动收益是主要影响因 素。 双鹭药业在2025年业绩预告中提到，本报告期确认损失金额中包括公司投资理财损失，该投资损失公司 目前正在以各种方式挽回。为维护公司利益，保护中、小股东利益不受损害，董事长徐明波自愿承诺该 投资理财无法挽回的差额部分最终确认后由其补足。 消息面上，双鹭药业发布2025年业绩预告显示，公司预计2025年归属净利润为-2亿元至-2.9亿元，比上 年同期下降170.03%至291.54%。 北京商报讯(记者丁宁)2月2日，双鹭药业（002038）盘中触及跌停，截至北京商报记者发稿，双鹭药业 报跌停价6.9元/股，跌幅为10.04%。 ...

Core Viewpoint - The company, Shuanglu Pharmaceutical, is expected to continue reporting losses in 2024, following its first loss in 20 years in 2023, with an anticipated increase in the amount of loss [1]. Financial Performance - The net profit attributable to shareholders is projected to be -29 million, a decline of 291.54% compared to the previous year [3]. - The net profit after deducting non-recurring gains and losses is expected to be -7 million, representing a decrease of 185.02% year-on-year [3]. - Basic earnings per share are forecasted to be -0.28, down from -0.19 in the previous year [3]. Reasons for Performance Decline - The decline in performance is attributed to two main factors: a decrease in product prices due to industry policy adjustments and market competition, leading to a 10% drop in sales gross margin [3]. - Non-recurring gains and losses are expected to reduce net profit by approximately 200 million, primarily due to losses from financial investments and changes in fair value of trading financial assets [3]. Financial Asset Investments - Financial asset investments have become a "double-edged sword" for the company, with significant fluctuations in stock prices of holdings like Fosun Pharma and Shouyao Holdings leading to a net profit reduction of 178 million [5]. - In the first three quarters of 2025, the company reported a net profit of 141 million, a year-on-year increase of 943.10%, mainly due to increased fair value gains from trading financial assets [5]. - The company confirmed a fair value loss of 122 million in the first nine months of 2024, while in the same period of 2025, it achieved a fair value gain of 128 million, a year-on-year growth of 204.93% [5]. Gross Margin Trends - The company's gross margin has been declining, from 81.56% in 2023 to 67.97% in 2024, and further down to 61.60% in the first three quarters of 2025 [5]. Company Background - Shuanglu Pharmaceutical, established on December 24, 1994, was listed on the Shenzhen Stock Exchange on September 9, 2004, and is recognized as the first high-tech enterprise from the capital to be listed [7]. - The company has developed and marketed over 70 products, including three national class I new drugs, with a strong portfolio in blood, oncology, cardiovascular, liver disease, diabetes, and kidney disease treatments [7].

南财智讯1月30日电，双鹭药业发布2025年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-20,000万元—-29,000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-7,000万元—-4,000万元。报告期内，受行业政策调整、市场竞争等因素影响，公司部分产品单价较 上年有所下降，导致本年度公司相关产品的销售毛利下降约10%；报告期内，公司非经常性损益合计减 少净利润约2亿元，其中：确认的理财投资损失与交易性金融资产等产生的公允价值变动收益是主要影 响因素。 ...

双鹭药业公告称，预计2025年归属于上市公司股东的净利润为 - 2.9亿元至 - 2亿元，较上年同期的 - 7406.57万元，下降291.54% - 170.03%；扣非净利润为 - 7000万元至 - 4000万元，较上年同期的8233.70 万元下降185.02% - 148.58%。业绩下降主因是行业政策和竞争使部分产品单价下降，销售毛利降约 10%，且非经常性损益使净利润减少约2亿元。董事长徐明波承诺补足投资理财无法挽回差额，先上缴 5000万元。 ...

证券代码：002038 证券简称：双鹭药业 公告编号：2026-001 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 二、与会计师事务所沟通情况 本期业绩预告相关的财务数据是公司财务部门初步测算的结果，未经过会计师事务所 审计。公司与会计师事务所就业绩预告有关的重大事项进行了初步沟通，双方不存在重大 分歧。 三、业绩变动原因说明 报告期内，受行业政策调整、市场竞争等因素影响，公司部分产品单价较上年有所下 降，导致本年度公司相关产品的销售毛利下降约 10%。 报告期内，公司非经常性损益合计减少净利润约 2 亿元，其中：确认的理财投资损失 与交易性金融资产等产生的公允价值变动收益是主要影响因素。 北京双鹭药业股份有限公司 2025 年度业绩预告 四、其他相关说明 本报告期确认损失金额中包括公司投资理财损失，该投资损失公司目前正在以各种方 式挽回。为维护公司利益，保护中、小股东利益不受损害，徐明波董事长自愿承诺该投资 理财 ...

Group 1: Flu Season Overview - The flu season in China has entered a high incidence period, with flu-like cases in southern and northern provinces reaching 10.3% and 9.1% of total emergency visits, respectively, both higher than the previous week [1] - The demand for flu prevention and control has surged, prompting pharmaceutical companies to increase inventory and supply across all segments, including vaccines, diagnostics, treatments, and drug distribution [1] Group 2: Prevention Efforts - Hualan Biological Engineering Co., Ltd. has reported a significant increase in public awareness regarding flu vaccination, leading to a rise in demand orders from disease control centers compared to the same period last year [1] - The company has efficiently utilized its cold chain logistics to meet the vaccination needs across the country [1] Group 3: Diagnostic Solutions - Shengxiang Biotechnology Co., Ltd. has developed a rapid nucleic acid testing solution for respiratory infections, covering various pathogens and is suitable for outpatient, emergency, and inpatient settings [1] - The company has seen an increase in shipments of respiratory products since October and is well-prepared to meet the testing demand during the flu season [1] Group 4: Treatment Options - The industry is witnessing a collaborative approach in flu treatment, combining Western and traditional Chinese medicine [2] - Beijing Shuanglu Pharmaceutical Co., Ltd. has reported an increase in orders for its flu medications, including Oseltamivir and immune enhancers [2] - Hunan Fangsheng Pharmaceutical Co., Ltd. has noted a significant improvement in sales of respiratory products in the fourth quarter, although overall sales for the year still require monitoring [2] Group 5: Drug Distribution - From November, the sales of flu medications, particularly Oseltamivir and Mabalaoshuai (Sufuda), have seen significant growth at the pharmacy chain, Lao Bai Xing [3] - The company has initiated supply assurance plans ahead of the respiratory disease peak season, ensuring stable market supply through predictive measures and increased inventory [3] - The overall pharmaceutical industry is responding to the flu season by ramping up production and inventory, which not only meets public medication needs but also drives company performance [3]

双鹭药业（002038.SZ）12月2日在投资者互动平台表示，本次减持已结束，限售股为高管锁定股，每年 年初重新以持股数量25%计算解除锁定。 每经AI快讯，有投资者在投资者互动平台提问：剩下的限售股什么时候可以上市流通？什么时候继续 减持？ （文章来源：每日经济新闻） ...

证券日报网讯12月2日，双鹭药业（002038）在互动平台回答投资者提问时表示，公司会在定期报告中 披露股东人数变化，截至2025年9月30日，公司股东总户数为54779户。 ...